GlassScriptPhysician profile
Dominique Phelps
NPI 1649983990
$1,724.51
in general payments reported to CMS, 2019-2025
22 companies · $659 in 2025
The $659 reported for 2025 was more than what 97% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $369 · 2024: $696 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $317.52 | 2023-2025 | Zynrelef |
| Biogen, INC. | $234.46 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $210.38 | 2023-2024 | Myfembree |
| Abbvie INC. | $169.41 | 2023-2025 | |
| Gynesonics, INC. | $138.71 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Minerva Surgical, INC | $108.76 | 2024 | |
| Eisai INC. | $107.16 | 2025 | |
| Ethicon US, LLC | $100.81 | 2025 | Surgiflo Hemostatic Matrix, Vistaseal |
| Hologic Sales and Service, LLC | $57.36 | 2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $41.01 | 2023-2024 | |
| Daiichi Sankyo INC. | $34.06 | 2023 | Injectafer |
| Antares Pharma, INC. | $32.42 | 2024-2025 | Xyosted |
| Novo Nordisk INC | $28.88 | 2024 | Wegovy |
| Coopersurgical, INC. | $19.72 | 2024 | Paragard T 380a |
| Boston Scientific Corporation | $18.45 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $16.10 | 2025 | Teriparatide |
| Dynavax Technologies Corporation | $15.37 | 2024 | Heplisav-B |
| Exeltis, USA INC. | $15.20 | 2023 | Slynd |
| Organon LLC | $15.13 | 2024 | |
| Pfizer INC. | $15.02 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.78 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominique Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.